Topic: 8. Chronic myeloid leukemia - Clinical Background: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the unregulated production of mature granulocytes and the BCR/ABL fusion gene presence. The age of presentation is between 45 to 55 years, however up to 30% of patients will be 60 years or over at diagnosis. It has been evidenced that the five-year survival rate is 80% greater with the development of Tyrosine Kinase Inhibitors (TKIs). Aims: The aim of this study was to determine factors associated with progression-free survival in chronic myeloid leukemia patients attended at FOSCAL in the 2013-2020. Methods: Secondary analysis of an anonymized database of CML patients attended at FOSCAL and included in RENEHOC (online platform). Univariate analysis was performed to characterize the population and bivariate for Kaplan-Meier survival and Hazard Ratio (HR) for the risk ratio. STATA V14 was used as a statistical package. Approval was given by the institutional ethics committee (06223/2022). Results: A total of 122 patients were attended at FOSCAL. The mean age was 56 years (SD 16) and 55% were women. Regarding to the risk assessment at diagnosis, 21.3% and 29.5% had a low score on Sokal and Hasford Index, respectively. During the first line of treatment, the most used drug was Imatinib (67.5%), followed by Dasatinib (20.5%) and Nilotinib (6.5%). Regarding optimal responses, 73.8% achieved hematological response, 62% cytogenetic response and 51% molecular response. Within the first line of treatment, 37.7% of patients had disease progression, in which 36.9% progressed to loss of hematologic response and 34.7% to loss of molecular response. Drug response loss was documented with Dasatinib (16%), Nilotinib (12.5%) and Imatinib (47.5%) with a statistically significant difference (p=0.03). It was observed that an age older than 65 years HR 0.77 (95%CI 0.18-3.31; p=0.72) promote PFS; while a high level on the Sokal and Hasford Index were against PFS HR 1.76 (95%CI 0.5-6.16; p=0.37) and HR 1.33 (95%CI 0.58-3.06; p=0.5) respectively; however, none of these results were statistically significant (Image 1). Summary/Conclusion: Even though data were not statistically significant, it was suggestive that age over 65 years and male gender represent greater progression-free survival, while a high score on the risk scales acts against this outcome.Keywords: Chronic myeloid leukemia, Survival